IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10292893" target="_blank" >RIV/00064203:_____/14:10292893 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/14:10292893

Result on the web

<a href="http://dx.doi.org/10.1182/blood-2013-06-509794" target="_blank" >http://dx.doi.org/10.1182/blood-2013-06-509794</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/blood-2013-06-509794" target="_blank" >10.1182/blood-2013-06-509794</a>

Result language

angličtina

Original language name

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL

Original language description

Childhood BCR-ABL1-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has an unfavorable outcome and shows high frequency of IKZF1 deletions. The prognostic value of IKZF1 deletions was evaluated in 2 cohorts of BCR-ABL1-positive BCP-ALL patients, before tyrosine kinase inhibitors (pre-TKI) and after introduction of imatinib (in the European Study for Philadelphia-Acute Lymphoblastic Leukemia [EsPhALL]). In 126/191 (66%) cases an IKZF1 deletion was detected. In the pre-TKI cohort, IKZF1-deleted patients had an unfavorable outcome compared with wild-type patients (4-year disease-free survival [DFS] of 30.0 +/- 6.8% vs 57.5 +/- 9.4%; P = .01). In the EsPhALL cohort, the IKZF1 deletions were associated with an unfavorable prognosis in patients stratified in the good-risk arm based on early clinical response (4-year DFS of 51.9 +/- 8.8% for IKZF1-deleted vs 78.6 +/- 13.9% for IKZF1 wild-type; P = .03), even when treated with imatinib (4-year DFS of 55.5 +/- 9.5% for IKZF1-del

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/GBP302%2F12%2FG101" target="_blank" >GBP302/12/G101: Molecular mechanisms of signaling through leukocyte receptors their role in health and disease.</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood

ISSN

0006-4971

e-ISSN

—

Volume of the periodical

123

Issue of the periodical within the volume

11

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

1691-1698

UT code for WoS article

000335847700016

EID of the result in the Scopus database

—